Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients by Villalba, Maria et al.
Oncotarget22752www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 16
Epigenetic alterations leading to TMPRSS4 promoter 
hypomethylation and protein overexpression predict poor 
prognosis in squamous lung cancer patients
Maria Villalba1,2,*, Angel Diaz-Lagares3,*, Miriam Redrado2, Arrate L. de 
Aberasturi1,2, Victor Segura4, Maria Elena Bodegas1, Maria J. Pajares1,2, Ruben 
Pio2,5, Javier Freire6, Javier Gomez-Roman6, Luis M. Montuenga1,2, Manel Esteller3, 
Juan Sandoval7,#, Alfonso Calvo1,2,#
1Department of Histology and Pathology, School of Medicine, University of Navarra, Pamplona, Navarra, Spain
2 IDISNA and Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), University of Navarra, 
Pamplona, Navarra, Spain
3 Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Catalonia, 
Spain
4 IDISNA and Bioinformatics Unit, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Navarra, 
Spain
5Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Navarra, Spain
6Department of Pathology, University Hospital Marques de Valdecilla, IDIVAL, Santander, Spain
7Department of Personalized Medicine, Epigenomics Unit, Medical Research Institute La Fe, Valencia, Spain
*Both authors should be considered as first authors
#Both authors should be considered as senior authors
Correspondence to: Juan Sandoval, e-mail: epigenomica@iislafe.es
Alfonso Calvo, e-mail: acalvo@unav.es
Keywords: TMPRSS4, epigenetics, promoter hypomethylation, squamous cell carcinoma, prognosis
Abbreviations: NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; ADC, adenocarcinoma; TCGA, The Cancer 
Genome Atlas; TSS, Transcription Start Site
Received: December 02, 2015    Accepted: February 18, 2016    Published: March 14, 2016
ABSTRACT
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related 
death worldwide, which highlights the need of innovative therapeutic options. 
Although targeted therapies can be successfully used in a subset of patients with 
lung adenocarcinomas (ADC), they are not appropriate for patients with squamous 
cell carcinomas (SCC). In addition, there is an unmet need for the identification of 
prognostic biomarkers that can select patients at risk of relapse in early stages. Here, 
we have used several cohorts of NSCLC patients to analyze the prognostic value of 
both protein expression and DNA promoter methylation status of the prometastatic 
serine protease TMPRSS4. Moreover, expression and promoter methylation was 
evaluated in a panel of 46 lung cancer cell lines. We have demonstrated that a high 
TMPRSS4 expression is an independent prognostic factor in SCC. Similarly, aberrant 
hypomethylation in tumors, which correlates with high TMPRSS4 expression, is an 
independent prognostic predictor in SCC. The inverse correlation between expression 
and methylation status was also observed in cell lines. In vitro studies showed that 
treatment of cells lacking TMPRSS4 expression with a demethylating agent significantly 
increased TMPRSS4 levels. In conclusion, TMPRSS4 is a novel independent prognostic 
biomarker regulated by epigenetic changes in SCC and a potential therapeutic target 
in this tumor type, where targeted therapy is still underdeveloped.
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INTRODUCTION
Lung cancer still remains as the most common cause 
of cancer death worldwide and presents a 5-year relative 
survival of around 18% [1, 2]. Among the different tumor 
subtypes, non-small cell lung cancer (NSCLC) is the 
most common one (accounting approximately for 85% of 
the cases) and comprises two major histological groups: 
adenocarcinomas (ADC, ~50%), and squamous cell 
carcinomas (SCC, ~30%). Late detection is a key factor 
related to its high mortality rate. In fact, it has been shown 
that earlier detection in screening programs mediated 
by spiral computed tomography reduces lung cancer 
deaths [3]. However, current therapeutic regimes are not 
sufficiently effective to significantly increase long term 
survival. For most patients with early NSCLC, surgical 
resection is the appropriate therapeutic option, although a 
considerable percentage of them (~30-70%, depending on 
the stage) will relapse overtime [2].
The implementation of targeted therapies aimed 
to inhibit specific mutations is mainly beneficial for a 
small group of patients with advanced NSCLC displaying 
adenocarcinoma histology [4], but not for patients with 
SCC [5]. Thus, clinical trials using targeted therapies 
against potential driver alterations have not been 
successful in SCC, and chemotherapy, or more recently 
immunotherapy [6], remains as the current option for 
these patients. Therefore, it seems clear that a better 
understanding of the biology of SCC is critical to identify 
effective therapeutic options.
Genetic abnormalities associated with SCC that 
are under-represented in ADC include PI3KCA, SOX2, 
and FGFR1 amplification, PTEN loss, and DDR2 and 
TP53 mutations [5]. Although patients with SCC cannot 
be currently selected for targeted therapy based on their 
molecular tumor profile, the aforementioned alterations 
and emerging targets constitute a window of opportunity 
for new therapies.
In a previous study, we demonstrated that TMPRSS4 
was highly upregulated in NSCLC, particularly in SCC, 
in comparison to non-malignant lung [7]. Moreover, we 
showed that increased TMPRSS4 mRNA levels were 
associated with poor prognosis in SCC patients [7]. 
TMPRSS4 has also been found upregulated in colon, 
pancreas, breast, cervix, thyroid and liver tumors [8, 9, 10, 
11]. This protein increases tumor growth and metastasis 
and induces the acquisition of epithelial to mesenchymal 
transition (EMT) [12, 13] and cancer stem cell (CSC) 
phenotypes [14].
Epigenetic control of gene expression acts as a 
switch to either induce or repress the transcriptional 
activity of multiple genes implicated in cancer 
development. Specific epigenetic mechanisms have 
been identified as responsible to regulate the expression 
of certain EMT-related genes [15, 16]. One of these 
epigenetic mechanisms is DNA methylation, which 
consists in the addition of a methyl group to the 5’ 
carbon of cytosine within cytosine-guanine dinucleotides 
(CpGs). Alterations in methylation patterns impair 
the transcriptional balance of cells and contribute to 
pathological conditions, including cancer initiation and 
progression [15].
In this study, we have evaluated the prognostic 
value of both TMPRSS4 protein levels and promoter 
methylation status in NSCLC patients. In vitro experiments 
were performed as well to demonstrate that TMPRSS4 
expression is regulated by promoter methylation. We have 
found that TMPRSS4 overexpression correlates with poor 
prognosis in NSCLC patients with squamous histology. 
Abnormal promoter hypomethylation was found in tissue 
samples from patients but not in non-malignant tissues 
and was inversely correlated with TMPRSS4 expression. 
Moreover, hypomethylation was associated with reduced 
relapse free survival in patients.
RESULTS
High TMPRSS4 protein expression is 
significantly associated with reduced RFS and 
OS in NSCLC patients with squamous histology
We first performed an immunohistochemical 
study on tissue microarrays (TMAs) containing NSCLC 
(n=79, stages I-II) and matched non-malignant (n=66) 
samples. The clinical and pathological characteristics of 
the NSCLC patients are shown in Supplementary Table 
1. In non-malignant lung samples, immunostaining was 
very low and only observed in some type II pneumocytes 
(Supplementary Figure 1A) and bronchiolar epithelial 
cells. In malignant specimens, the signal was found 
in tumor cells in both adenocarcinomas (ADC) and 
squamous cell carcinomas (SCC) (Figure 1A). In some 
SCC, immunostaining could also be detected in the 
plasma membrane of tumor cells. Tumors showed a very 
significant increase in H-score (p<0.001) in comparison 
with non-malignant samples (Supplementary Figure 1B). 
NSCLC patients were dichotomized into two groups: high 
(n=40) and low (n=39) TMPRSS4 expression, according 
to the median value of the H-score.
We then evaluated the relationship between 
TMPRSS4 protein expression and clinicopathological 
characteristics of the patients. No association between 
TMPRSS4 expression and any of the clinicopathological 
characteristics analyzed was found except for the 
histological type (p=0.017; Supplementary Table 2). 
Remarkably, the frequency of tumors with high TMPRSS4 
was significantly higher in SCC than in ADC tumors.
Regarding prognosis, patients with high levels 
of TMPRSS4 showed significantly shorter relapse free 
survival (RFS, p=0.029) and overall survival (OS, 
p<0.001) than those with low levels (Figure 1B-1C). We 
next stratified the patients according to their histological 
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Figure 1: High TMPRSS4 protein expression correlates with poor prognosis. A. Immunohistochemical staining for TMPRSS4 
protein in adenocarcinoma (ADC, left panel) and squamous cell carcinoma (SCC, right panel). Strong membrane immunoreactivity was 
observed in some SCC samples. B-C. Kaplan-Meier curves in the whole set of patients showing that high TMPRSS4 levels are significantly 
associated with reduced relapse free survival (RFS) and overall survival (OS). D-E. In patients with ADC histology no statistical differences 
were observed for either RFS or OS in relation to TMPRSS4 protein levels. F-G. In SCC, high TMPRSS4 levels were very significantly 
associated with lower OS (p=0.004), and were borderline for RFS (p=0.058). Differences between groups were assessed by the logRank test.
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tumor type. In ADC patients, no statistical association was 
found between TMPRSS4 levels and either RFS (p=0.492) 
or OS (p=0.122) (Figure 1D-1E). On the contrary, in 
SCC patients, high TMPRSS4 levels were significantly 
associated with reduced OS (p=0.004) and were close to 
statistical significance for RFS (p=0.058) (Figure 1F-1G).
When considering only the cases corresponding to 
stage I patients (n=52), we found that high TMPRSS4 
protein expression was significantly correlated with 
worse OS (p=0.001) and borderline for RFS (p=0.058) 
(Supplementary Figure 1C-1D). Similar results were 
obtained when the analysis was performed exclusively in 
stage II patients (n=27) (Supplementary Figure 1E-1F). In 
these latter sets of patients we did not perform the analysis 
after stratification by histological types due to the low 
number of cases.
To rule out the possibility that post-surgery treatment 
with chemotherapy or radiotherapy could influence the 
results on survival, we performed logRank tests excluding 
patients treated with post-surgery adjuvant therapy. As 
shown in Supplementary Figure 1G, results were similar 
to those found for the whole cohort of patients, indicating 
that high TMPRSS4 levels were significantly associated 
with reduced RFS and OS in SCC and all NSCLC patients. 
In this case, a significant association (p=0.023) between 
high TMPRSS4 expression and OS was also observed for 
ADC.
We next evaluated if TMPRSS4 could be considered 
as an independent prognostic factor in NSCLC using Cox 
regression analyses (Table 1). In the univariate analysis, 
high TMPRSS4 levels were significantly associated with 
reduced RFS (HR=2.2; 95%CI: 1.1-4.5; p=0.033) and 
OS (HR=7.1; 95%CI: 2.0-25.6; p=0.003). Age, gender, 
smoking status, post-surgery radio or chemotherapy, 
histology, grade and stage were not found as predictors 
of either RFS or OS. For the multivariate analysis, 
significant variables as well as variables considered 
clinically relevant and close to statistical significance 
were included. Multivariate analysis in the whole cohort 
of patients indicated that TMPRSS4 was an independent 
prognostic factor for both RFS (HR: 2.3; 95%CI: 1.1-4.8; 
p=0.020) and OS (HR: 6.0; 95%CI: 1.6-2.2; p=0.007). 
Stage was also found as a significant prognostic factor 
of OS (HR: 3.1; 95%CI 1.1-9.0; p=0.041). We then 
conducted univariate and multivariate analyses after 
stratification of patients according to histological subtypes. 
Table 2 shows that, in the univariate analysis performed 
in SCC, high TMPRSS4 was found to be associated with 
reduced RFS (HR: 5.3; 95%CI: 1.1-25.3; p=0.036). In 
multivariate analysis we confirmed this association in 
SCC (HR: 5.4; 95%CI: 1.1-25.7; p=0.035). Regarding 
OS in SCC, univariate and multivariate analyses could 
not be performed, since data did not fulfill the criteria 
of proportional hazards (due to the lack of events in the 
group of patients with low TMPRSS4 expression; see 
Figure 1G). For ADC, no statistical association between 
TMPRSS4 protein expression and either RFS or OS was 
observed (Table 2).
All these data indicate that TMPRSS4 is an 
independent prognostic factor at early stages in NSCLC, 
associated with poor prognosis in SCC patients.
Aberrant hypomethylation of TMPRSS4 
promoter in NSCLC
In order to ascertain the possible cause of TMPRSS4 
overexpression in lung cancer patients, we evaluated 
through bioinformatic analyses using public databases 
(COSMIC, CCLE, IGDB.NSCLC) possible genetic 
alterations (gene amplification, mutations, rearrangements) 
of TMPRSS4 in NSCLC. Analysis showed that these 
changes were very infrequent and unlikely to explain 
TMPRSS4 upregulation (data not shown). We then 
hypothesized that increased TMPRSS4 expression could 
be due to epigenetic modifications. The TMPRSS4 
promoter does not contain a canonical CpG island, but 
gene overexpression through hypomethylation in non-CpG 
islands has been previously described [17]. Based on this 
fact, we studied TMPRSS4 promoter methylation status in 
NSCLC and normal samples using the 450k methylation 
array (FP7 CURELUNG discovery cohort). We analyzed 
methylation levels (ß-values) of CpGs located at the 
following positions from the Transcription Start Site 
(TSS): CpG -268 bp (CG13159318 probe in the 450k 
methylation array), CpG -172 bp (CG05775918), CpG 
-116 bp (CG03634928), CpG -99 bp (CG27300950), CpG 
-70 bp (CG25116503), CpG +151 bp (CG22957898) and 
CpG +271 bp (CG05416223). The different CpGs were 
grouped into 3 sets according to their position: 5’ UTR, 
TSS200 (from the TSS to nucleotide -200) and TSS1500 
(from -200 to -1500 upstream the TSS). A significant and 
consistent decrease in methylation levels for all the CpGs 
was detected in both ADC and SCC as compared to non-
malignant tissues (Figure 2A).
To validate this result, DNA samples from another 
cohort of 88 NSCLC patients (Supplementary Table 1 for 
patient’s characteristics) was analyzed by pyrosequencing 
of CpGs -116 (CG03634928) and -99 (CG27300950). We 
selected these CpGs for technical reasons dealing with 
conditions required for primer design and for being close 
to the TSS. As shown in Figure 2B, methylation levels 
in both ADC and SCC were very significantly reduced 
(p<0.001) with respect to those found in non-malignant 
lungs. To further support these results, we retrieved data 
from The Cancer Genome Atlas TCGA [18] and evaluated 
methylation levels of the TMPRSS4 promoter. In this 
dataset, probes CG13159318 and CG03634928 were not 
available. Figure 2C shows that, in agreement with the 
other cohorts, significant aberrant TMPRSS4 promoter 
hypomethylation (p<0.001) was observed for all the 
methylation sites studied in both ADC and SCC.
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Table 1: Univariate and multivariate Cox regression analysis to study the effect of TMPRSS4 expression on RFS and 
OS in NSCLC patients
RFS
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age
 < 65
 ≥ 65 1,359 0.671-2.752 0.395
Gender
 Female
 Male 0.759 0.311-1.854 0.545
Smoking Status
  Never smoker
 Former smoker 0.487 0.179-1.326 0.159
  Current smoker 0.990 0.330-2.966 0.985
Radiotherapy*
 No
 Yes 1,954 0.683-5.594 0.212
Chemotherapy*
 No
 Yes 1,553 0.757-3.188 0.230
Histology
 ADC
 SCC 0.924 0.433-1.975 0.839
 Others 2,718 0.781-9.454 0.116
Grade
  WD/MD
 PD 1,300 0.626-2.698 0.481
Stage
 I
 II 1,730 0.845-3.540 0.134 1,933 0.956-3.908 0.066
TMPRSS4
 Low
 High 2,187 1.064-4.494 0.033 2,335 1.142-4.775 0.020
(Continued)
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OS
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age
 < 65
 ≥ 65 1,969 0.701-5.536 0.199
Gender
 Female
 Male 2,579 0.339-19.637 0.360
Smoking Status
  Never smoker
 Former smoker 1,701 0.219-13.187 0.611
  Current smoker 1,458 0.151-14.044 0.744
Radiotherapy*
 No
 Yes 2,742 0.766-9.821 0.121
Chemotherapy*
 No
 Yes 0.866 0.275-2.724 0.805
Histology
 ADC
 SCC 1,412 0.494-4.034 0.519
 Others 2,108 0.253-17.557 0.490
Grade
  WD/MD
 PD 2,831 0.948-8.460 0.062 2,102 0.696-6.347 0.188
Stage
 I
 II 2,646 0.957-7.315 0.061 3,072 1.048-9.007 0.041
TMPRSS4
 Low
 High 7,136 1.991-25.574 0.003 5,970 1.634-2.181 0.007
WD = well differentiated; MD = moderately differentiated; PD = poorly differentiated. * indicates that radiotherapy or 
chemotherapy were applied post-therapy.
Oncotarget22758www.impactjournals.com/oncotarget
Table 2: Univariate and multivariate Cox regression analyses to study the effect of TMPRSS4 expression in ADC 
and SCC patients
ADC
RFS OS
Univariate analysis Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P HR 95% CI P
Age
 < 65
 ≥ 65 0.876 (0.333-2.305) 0.788 0.429 (0.082-2.246) 0.316
Gender
 Female
Male 0.556 (0.194-1.596) 0.275 1,526 (0.183-1.272) 0.696
Smoking Status
Never smoker
Former smoker 0.504 (0.154-1.649) 0.257 1,276 (0.149-1.096) 0.824
Current smoker 1,481 (0.366-5.991) 0.582 1,371 (0.086-2.193) 0.824
Radiotherapy*
No
Yes 2,253 (0.506-10.031) 0.286 1,957 (0.233-16.410) 0.536
Chemotherapy*
No
Yes 1,552 (0.585-4.118) 0.377 0.764 (0.148-3.945) 0.748
Grade
  WD/MD
 PD 1,991 (0.719-5.514) 0.185 10,190 (1.188-87.416) 0.034 6,808 (0.723-64.083) 0.094
Stage
 I
 II 1,996 (0.763-5.217) 0.159 2,576 (0.575-11.530) 0.216 2,423 (0.385-15.249) 0.346
TMPRSS4
 Low
 High 1,403 (0.532-3.696) 0.494 3,078 (0.687-13.801) 0.142 1,875 (0.343-10.254) 0.469
SCC
RFS
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age
 < 65
 ≥ 65 1,794 (0.519-6.197) 0.355
Gender
 Female
Male ‡ ‡ ‡
Smoking Status
Never smoker
Former smoker
Current smoker 1,747 (0.529-5.766) 0.360
(Continued)
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SCC
RFS
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Radiotherapy*
No
Yes 1,743 (0.220-13.826) 0.599
Chemotherapy*
No
Yes 0.556 (0.071-4.346) 0.576
Grade
  WD/MD
 PD 0.742 (0.217-2.541) 0.635
Stage
 I
 II 1,200 (0.317-4.541) 0.788 1,288 (0.336-4.938) 0.712
TMPRSS4
 Low
 High 5,317 (1.117-25.301) 0.036 5,381 (1.127-25.694) 0.035
WD = well differentiated; MD = moderately differentiated; PD = poorly differentiated; * indicates that radiotherapy or 
chemotherapy were applied post-therapy. ‡ indicates that the test was not applicable because there were only two females in 
that group.
Therefore, we conclude that TMPRSS4 promoter 
is methylated in normal lung, whereas an abnormal 
hypomethylation occurs in tumors, which could constitute 
an oncogenic mechanism, as described for other tumor 
promoting genes [19].
Hypomethylation of TMPRSS4 promoter 
significantly correlates with RFS in NSCLC 
patients
We next investigated whether promoter 
hypomethylation had an effect on clinical outcome. 
Patients were categorized based on a 50% methylation 
threshold. The prognostic value of loss of methylation 
for each of the 7 probes analyzed was assessed in the 
CURELUNG cohort by logRank test and multivariate 
Cox regression for correlation with RFS, in those patients 
where clinical information was available (ADC, n=155 
and SCC, n=43). Data on OS was not available in this 
cohort.
Table 3 shows that, considering results from 
both logRank and multivariate analyses, there was a 
DNA region corresponding to probes CG03634928 to 
CG05416223 that contained CpGs whose hypomethylation 
(β<0.5) predicts poor prognosis in SCC tumors. In the 
multivariate analysis, hypomethylation of any of the last 4 
consecutive CpGs (CG27300950 to CG05416223 probes) 
was an independent predictor of reduced RFS in this 
tumor type. In the logRank test, low methylation levels 
were found to be associated with worse prognosis for the 
following probes: CG03634928 (p=0.046), CG25116503 
(p=0.008), CG22957898 (p=0.007) and CG05416223 
(p=0.014). Differences for CG27300950 were close to 
statistical significance (p=0.053). Figure 3 illustrates 
Kaplan-Meier curves for the last 4 consecutive CpGs in 
SCC patients in comparison to those obtained in ADC.
Methylation patterns regarding prognosis observed 
for SCC were different in ADC tumors. In the multivariate 
analyses, TMPRSS4 promoter hypomethylation was 
not an independent prognostic factor for any of the 
CpGs analyzed in ADC (Table 3). In the logRank 
test, low methylation levels of CpGs corresponding to 
CG13159318, CG05775918 and CG27300950 probes 
were significantly associated with shorter RFS (Table 3 
and Figure 3).
When considering all NSCLC samples, 
hypomethylation was an independent predictor of reduced 
RFS only for probe CG27300950 (p=0.015). The logRank 
tests showed statistical differences in the same CpGs 
that were obtained for ADC, plus probe CG25116503. 
Supplementary Figure 2A-2D illustrates Kaplan-Meier 
curves for all NSCLC patients corresponding to the last 4 
consecutive CpGs (CG27300950 to CG05416223 probes).
These results highlight the differences in 
hypomethylation patterns related to prognosis found for 
SCC and ADC. Taking into account results from both 
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Figure 2: TMPRSS4 promoter hypomethylation is consistently found in NSCLC patients in comparison with their 
non-malignant counterparts. A. Seven CpGs were analyzed using the 450k methylation array in the CURELUNG cohort. All CpGs 
showed hypomethylation in both ADC and SCC in comparison with non-malignant lung tissue. B. Pyrosequencing in the validation cohort 
of two consecutive CpGs located at the TSS200 region showed a similar hypomethylation pattern in both ADC and SCC samples. C. 
Data from TCGA, where probes CG13159318 and CG03634928 were not available, confirmed a very significant reduction in TMPRSS4 
promoter methylation levels in malignant samples.
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multivariate analyses and longRank tests we conclude that 
loss of TMPRSS4 promoter methylation in CpGs spanning 
from -116 bp to +271 bp relative to the TSS (CG03634928 
to CG05416223 probes) consistently predicts poor 
outcome in SCC.
TMPRSS4 mRNA levels inversely correlate with 
the degree of promoter methylation in NSCLC 
patients and cell lines
We then retrieved data from both TMPRSS4 
expression and promoter methylation status available 
at TCGA (ADC, n=454 and SCC, n=370) to perform 
correlation analyses with those CpGs that were localized 
between -116 bp to +271 bp relative to the TSS and 
were significantly associated with poor prognosis in the 
multivariate analysis.
Figure 4A-4B shows a significant inverse correlation 
between TMPRSS4 expression and methylation status 
for the average value of the 4 probes analyzed (r=-0.38, 
p<0.0001 for ADC; r=-0.34, p<0.0001 for SCC). A 
significant inverse correlation between expression and 
methylation status considering separately each of the 
individual probes was also observed (p<0.0001 for all of 
them). Figure 4C-4F shows the probes with the highest 
correlation values: CG27300950 (r=-0.35 for ADC; r=-
033 for SCC; Figure 4C-4D) and CG05416223 (r=-0.62 
for ADC; r=-048 for SCC; Figure 4E-4F).
We also evaluated both expression and promoter 
methylation status in a panel of 46 lung cancer cell 
lines. Firstly, analysis of the methylome using the 
450k methylation array in these cells showed different 
methylation patterns of TMPRSS4 promoter (Figure 
5A). Classification according to an unsupervised 
hierarchical cluster analysis based on methylation status 
separated 3 different groups: (1) cells with consistent 
TMPRSS4 promoter hypomethylation in all or most of 
the 7 CpGs analyzed; (2) cells with predominant promoter 
methylation; and (3), cells with a less defined pattern.
For analysis using bisulfite sequencing we selected 
16 cell lines representative of the 3 different clusters 
previously identified in the 450k methylation array 
(Figure 5B). Sequencing of the CpG sites located at 
-172 bp (CG05775918), -116 bp (CG03634928), -99 bp 
(CG27300950), -70 bp (CG25116503), +106 bp, +123 bp 
and +151 bp (CG22957898) relative to the TSS revealed 
the following results: extensive methylation was observed 
for cells belonging to cluster 2 in the array (H23, H1703, 
H520, H226, A549 and H446), whereas cells with no 
promoter methylation were coincident with those included 
in cluster 1, confirming our previous results obtained with 
the 450k methylation array.
Methylation status was next validated by 
pyrosequencing of the CpGs located at -116 bp and -99 
bp and results were correlated with those obtained in 
the array. As shown in Supplementary Figure 2E, there 
was a significant correlation between methylation status 
analyzed by both techniques (r=0.80; p<0.0001).
We then quantified TMPRSS4 mRNA levels 
by real time PCR in the whole set of cell lines and 
performed Spearman’s test to correlate expression with 
degree of methylation (average of the 2 CpGs evaluated 
Table 3: Log Rank P values and Cox regression analysis to study patient’s RFS in relation to methylation status in 
CpG sites
All samples ADC SCC
logRank Multivariate analysis logRank Multivariate analysis logRank Multivariate analysis
TargetID Location* Group P HR 95% CI P P HR 95% CI P P HR 95% CI P
CG13159318 -268 TSS1500 0.004 1.28 (0.85-1.93) 0.235 0.030 1.30 (0.79-2.13) 0.296 0.220 1.69
(0.74-
3.83) 0.211
CG05775918 -172 TSS200 0.003 1.42 (0.91-2.21) 0.122 0.002 1.69 (0.97-2.94) 0.063 0.910 1.30
(0.59-
2.87) 0.520
CG03634928 -116 TSS200 0.065 1.21 (0.78-1.87) 0.389 0.230 1.13 (0.68-1.89) 0.640 0.046 1.87
(0.78-
4.48) 0.162
CG27300950 -99 TSS200 0.001 1.66 (1.11-2.51) 0.015 0.009 1.42 (0.86-2.35) 0.167 0.053 3.36
(1.50-
7.46) 0.003
CG25116503 -70 TSS200 0.034 1.31 (0.87-1.99) 0.198 0.190 1.06 (0.64-1.73) 0.828 0.008 3.23
(1.40-
7.46) 0.006
CG22957898 +151 5'UTR 0.050 1.19 (0.78-1.81) 0.417 0.290 0.96 (0.58-1.57) 0.860 0.007 3.09
(1.30-
7.30) 0.011
CG05416223 +271 5'UTR 0.570 0.98 (0.65-1.49) 0.938 0.370 0.80 (0.49-1.30) 0.368 0.014 4.69
(1.26-
17.54) 0.021
*bp relative to the TSS.
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Figure 3: Association between TMPRSS4 promoter methylation status and RFS in NSCLC patients. The previously 
defined 50% methylation cutoff value (β<0.5) was used to categorize patients into two groups (high and low methylation status). The 
following probes were depicted in ADC and SCC graphics, respectively: CG27300950 A-B. CG25116503 C-D. CG22957898 E-F. and 
CG05416223 G-H. Significant reduction in RFS was found for SCC patients with low TMPRSS4 promoter methylation in 3 out of 4 CpGs 
analyzed. Only CG27300950 was significantly different between groups in ADC and close to statistical significance in SCC.
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Figure 4: TMPRSS4 expression (RNA-Seq) inversely correlates with promoter methylation (450k methylation array). 
A. Average methylation values of CpGs corresponding to probes CG27300950 to CG05416223 (group of 4 CpGs that predicted poor 
prognosis in SCC in the multivariate analysis) were first considered for the analysis in ADC samples. A significant inverse correlation 
between methylation status and expression is observed. B. A similar result is found for SCC. Correlation analysis using values from 
individual probes follows a similar pattern. Examples of CG27300950 C. ADC; D. SCC) and CG05416223 (E. ADC; F. SCC) are shown. 
Data retrieved from TCGA.
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Figure 5: TMPRSS4 promoter methylation status in a panel of NSCLC cell lines. A. Methyloma analysis of 46 cell lines 
was carried out with the 450k methylation array and hierarchical cluster analysis separated 3 groups: (1, n=17) cells with promoter 
hypomethylation in all or most of the 7 CpGs analyzed; (2, n=15) cells with predominant promoter methylation; and (3, n=14) cells with no 
clear pattern of methylation. B. Bisulfite genomic sequencing of TMPRSS4 promoter in human lung cancer cell lines. Location of bisulfite 
genomic sequencing PCR primers (black horizontal arrows), CpG dinucleotides (vertical lines) and the transcriptional start site (TSS, grey 
arrow) are shown. Ten single clones are represented for each sample. Presence of unmethylated or methylated CpGs is indicated by white or 
black squares, respectively. The CpG sites analyzed are located at -172 bp, -116 bp, -99 bp, -70 bp, +106 bp, +123 bp and +151 bp from the 
TSS (chr11:118.077.075), according to the current version of UCSC Genome Browser (GRCh38/hg38). Red circles represent the location 
of three consecutive probes (CG03634928, CG27300950 and CG25116503) detected by the 450k methylation array that correspond to 
-116 bp, -99 bp and -70 bp from the TSS, respectively. C. Graphic representation of inverse correlation between TMPRSS4 expression 
(evaluated by real time PCR) and methylation status (pyrosequencing) of the 46 cell lines. Spearman’s correlation r=-0.64; p<0.0001.
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by pyrosequencing). Figure 5C shows that there was 
a statistically significant inverse correlation (r=-0.64; 
p<0.0001) between TMPRSS4 expression and promoter 
methylation.
To test whether demethylation of TMPRSS4 
promoter would result in increased TMPRSS4 levels, 
we treated cell lines lacking TMPRSS4 expression with 
the demethylating agent 5-aza-2′-deoxycytidine. After 
48 hours of treatment with 2 or 4 μM, overexpression 
of TMPRSS4 mRNA was observed in all cell lines 
(Supplementary Figure 2F). Pyrosequencing analysis 
(average of the 2 CpG analyzed) confirmed that the degree 
of TMPRSS4 promoter methylation was significantly 
decreased in most of the treated cell lines (Supplementary 
Figure 2G).
Taken together, all these results suggest that 
TMPRSS4 expression is controlled by promoter 
methylation, and that abnormal hypomethylation results 
in TMPRSS4 overexpression.
DISCUSSION
Expression of the serine protease TMPRSS4 
is highly increased in a variety of solid tumors and is 
associated with poor prognosis in some cancer types 
such as breast, colon, cervix, thyroid and liver [8, 11]. 
Our present study shows for the first time that TMPRSS4 
is an independent prognostic indicator of reduced 
survival in patients with squamous NSCLC at early 
stages, thus validating our previous findings by mRNA 
analysis [7]. The protumorigenic and prometastatic 
role of TMPRSS4 described in experimental models 
may influence tumor features leading to worse clinical 
outcome. In particular, this protease induces EMT, cell 
motility and invasion in colon [12], lung [7, 20] and 
liver [11] cancer. Moreover, we have recently shown 
[14] that TMPRSS4 expression leads to the acquisition 
of a CSC phenotype and that levels in patients correlate 
with those of other CSC markers that predict poor 
prognosis, such as ALDH and OCT4 [21, 22].
Thus far, the molecular mechanisms that may 
explain why TMPRSS4 is highly expressed in lung tumors 
are largely underexplored. Hamamoto et al., have shown 
that TMPRSS4 is upregulated in NSCLC by epigenetic 
silencing of the tissue factor pathway inhibitor-2 [23]. We 
now provide evidence showing epigenetic changes that 
elicit TMPRSS4 promoter hypomethylation in NSCLC. 
Moreover, we show that TMPRSS4 promoter methylation 
is inversely correlated with mRNA expression in both 
NSCLC patients and cell lines, which suggests that loss 
of methylation could constitute a main mechanism to 
express TMPRSS4. Although other molecular alterations 
might also influence expression of this protease in cancer, 
bioinformatic analyses using different public sources seem 
to indicate that genetic alterations of this protease are rare 
in NSCLC. Therefore, epigenetic deregulation is likely 
to be the main cause of TMPRSS4 overexpression in this 
tumor type.
Results from the 450k methylation array, and both 
bisulfite sequencing and pyrosequencing in our study 
show that, although TMPRSS4 promoter does not contain 
canonical CpG islands, there are relevant methylation 
regions in the TMPRSS4 promoter, which include CpGs 
located at positions -116 bp to +271 bp relative to the TSS. 
Analyses of ENCODE and transcription factor binding 
sites prediction databases (cREMaG and MotifScanner) 
suggest a possible involvement of transcription factors 
related to proliferation, EMT and inflammation (e.g. 
Zeb1, E2F1, Myc, NFkB and STAT3), whose binding 
in the vicinity of those CpGs could be mediated by 
hypomethylation. Future studies should determine whether 
binding of these factors is epigenetically regulated 
and whether this would have an effect on TMPRSS4 
expression.
DNA hypomethylation is being increasingly 
acknowledged as a recurrent event in cancer, a mechanism 
that frequently affects oncogenes and tumor-promoting 
genes involved in proliferation, migration and metastasis 
[15]. In a genome-wide DNA methylation profiling study 
conducted in stage I NSCLC, authors described promoter 
hypermethylation in 496 CpGs and hypomethylation in 
373 CpGs, which shows that frequency of both epigenetic 
modifications is similar [24]. Other tumor promoter genes 
described in NSCLC, such as ELMO3 and 14-3-3s, show 
similar patterns of promoter methylation/expression to 
those observed for TMPRSS4 [25, 26].
Our study shows that both TMPRSS4 
hypomethylation and high protein expression predict 
shorter RFS in patients with SCC, but results are not 
so consistent for patients with ADC. Over the past 
few years, different studies have described genomic 
alterations associated with SCC that are under-
represented in ADC, although targeted therapy based on 
these alterations is still to be developed [5]. Deciphering 
molecular mechanisms causative of tumor progression 
and metastasis will help establishing novel therapeutic 
options for patients with SCC tumors. In this regard, 
therapeutic approaches in TMPRSS4-expressing SCC 
tumors should be investigated in future studies. This 
could be achieved with small molecules, but based on 
our study, targeted restoration of promoter methylation 
may be an alternative therapeutic strategy. Epigenetic 
editing approaches are currently being investigated for 
specific modulation of gene expression. CRISPR/Cas9 
and zinc fingers (ZF) editing methodologies have been 
used to modulate the activity of DNA methyltransferases 
(DNMTs) in a gene-specific way. For example, 
Stolzenburg et al., have recently developed a biological 
tool that links ZF proteins with DNMT3A to methylate 
the DNA promoter of the SOX2 oncogene, which results 
in efficient gene expression silencing and antitumor 
effects in vivo [27].
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In conclusion, we show for the first time that there 
is an epigenetic DNA hypomethylation of the TMPRSS4 
promoter, a mechanism that may explain the TMPRSS4 
overexpression found in NSCLC. We also demonstrate 
that both TMPRSS4 levels and promoter methylation 
status are useful biomarkers to predict poor prognosis in 
patients with lung SCC at early stages.
MATERIALS AND METHODS
Patients
To detect TMPRSS4 by immunohistochemistry, 
tissue microarrays (TMAs) containing samples from 
NSCLC (n=79) and matched non-malignant lung 
tissues (n=66) were used. Tumor samples were obtained 
from patients diagnosed at stage I or II who did not 
receive neoadjuvant therapy prior to surgery. Detailed 
histopathological and clinical characteristics of the 
patients are summarized in Supplementary Table 1. The 
TMAs included representative areas of the specimens 
with cores from each tumor at 3 different sites. Samples 
were obtained from patients who underwent tumor 
resection surgery at Clinica Universidad de Navarra 
(Pamplona, Spain). The study protocol was approved 
by the Institution and written informed consent was 
obtained for each patient. Immunostaining was carried 
out following standard procedures. For more details about 
immunohistochemistry, see Supplementary Materials and 
Methods (Suppl. M&M). Samples were blindly evaluated 
by two observers (M.R. and M.E.B.) considering both 
staining extension and intensity as previously described 
[28]. An H-score was established for each sample using 
those parameters. The median value was chosen as the 
cutoff to establish low and high TMPRSS4 expression 
levels.
For promoter methylation analysis, two cohorts 
of patients were used. We first evaluated our previously 
published FP7 CURELUNG discovery cohort of lung 
tumors (n=444 patients) and non-tumor lung tissue 
samples (n=25) [29] with the 450k methylation array to 
quantify the degree of methylation in each sample set. A 
subset of the aforementioned discovery cohort consisting 
in cancer tissues from 198 surgically resected NSCLC 
patients was also used for assessing the prognostic value of 
TMPRSS4 promoter methylation on relapse free survival. 
The clinical characteristics of these NSCLC patients are 
available in our previous publication [29]. A second cohort 
(validation cohort) was used to study TMPRSS4 promoter 
methylation status by pyrosequencing, which included 88 
NSCLC samples from Clinica Universidad de Navarra. 
Characteristics of this cohort of patients are summarized 
in Supplementary Table 1.
This work followed REMARK (REporting 
recommendations for tumour MARKer prognostic studies) 
criteria for tumor marker studies.
Cell lines, cluster analysis and treatment with a 
demethylating agent
A panel of 46 cell lines corresponding to different 
lung cancer histological types was included in this 
study (Supplementary Table 3). Of these, 16 cell lines 
representative of the 3 different methylation-based clusters 
identified in the 450k methylation array (see Results) were 
chosen for DNA methylation analysis by bisulfite genomic 
sequencing.
For treatments with 5-aza-2’deoxycitidine (Sigma, 
St. Louis, MO, USA), A549, H82, H23, H520 and 
H460 cells were cultured in RPMI and exposed to the 
drug at 2 μM and 4 μM concentrations. After 48h, cells 
were trypsinized and pellets were washed with PBS and 
maintained at -80ºC for RNA and DNA extraction.
DNA and RNA isolation and real time PCR
Genomic DNA was extracted from FFPET 
(formalin-fixed-paraffin-embedded tissue) using Cobas® 
DNA Sample Preparation Kit, and RNA was obtained 
from frozen pellets using the Nucleospin RNA kit. 
Real time PCR was performed with SYBR green using 
standard protocols and primer sequences are shown in 
Supplementary Table 4. For detailed protocols see Suppl. 
M&M.
DNA methylation analysis by bisulfite genomic 
sequencing
The Methyl Primer Express v1.0 software (Applied 
Biosystems) was used to identify the TMPRSS4 promoter 
CpGs and to design specific primers for the methylation 
analysis (Supplementary Table 4). None of the primers 
covered any CpG. Approximately 1 μg of DNA from 
each human lung cancer cell line was subjected to sodium 
bisulfite treatment using the EZ DNA Methylation-Gold 
kit (Zymo Research). A 394-bp fragment, −199 bp to 
+195 bp relative to the transcription start site (TSS), was 
amplified using 2 μL of bisulfite-converted DNA with 
Immolase Taq polymerase (Bioline) at 60ºC for 35-40 
cycles. The resulting PCR products were gel-purified 
(2% agarose) with NucleoSpin® Gel and PCR Clean-up 
(Macherey-Nagel) and then cloned into the pGEMT Easy 
Vector System (Promega) according to the manufacturer’s 
protocol. In all the samples, 10 colonies were randomly 
chosen, and DNA was purified using NucleoSpin® 
96 Plasmid (Macherey-Nagel) and sequenced. After 
sequencing analysis, results were transformed into 
percentages of CpGs showing methylation.
DNA methylation analysis by bisulfite 
pyrosequencing
Quantitative DNA methylation analysis of 
the TMPRSS4 promoter was performed by bisulfite 
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pyrosequencing of two consecutive potentially methylated 
cytosines located at −116 bp and -99 bp relative to the 
TSS. Bisulfite conversion of 500 ng of each DNA 
sample was performed with EZ DNA Methylation-Gold 
Kit (Zymo Research) according to the manufacturer's 
recommendations. Primer sequences (Supplementary 
Table 4) were designed with PyroMark Assay Design 2.0 
(Qiagen). None of the PCR primers covered any CpG. 
PCR for TMPRSS4 promoter was performed with 1 μl 
of bisulfite converted DNA with biotinylated primers 
using an annealing temperature of 60ºC and 50 cycles. 
PCR products were verified on 2% agarose gels before 
pyrosequencing analysis. Pyrosequencing was performed 
using a Pyro Gold SQA™ Reagent Kit (Qiagen) in a 
PyroMark Q96 System version 2.0.6 (Qiagen) according 
to the manufacturer’s instructions. CpG site methylation 
quantification was obtained using Pyro Q-CpG 1.0.9 
(Qiagen).
Bioinformatic and statistical analysis
Different statistical methods were applied 
depending on the type of experimental data. The 
processed transcriptomic (RNA-Seq experiments) 
and DNA methylation data generated by the 450k 
methylation array for lung cancer datasets were 
downloaded from the public TCGA project portal 
[18]. Bioinformatic analysis was carried out with R 
and Bioconductor (freely available). The analysis of 
differential methylation patterns was performed with 
LIMMA (Linear Models for Microarray Data) [30]. 
Probes were selected as significant using the criteria of 
FDR<5%. The association between RNA-Seq expression 
levels and microarray methylation levels were tested 
with Pearson’s correlation.
Correlation analysis between TMPRSS4 expression 
and promoter methylation in cell lines was assessed with 
Spearman’s test and cells were clustered based on their 
methylation status by hierarchical clustering analysis 
using Euclidean distance and complete linkage analysis.
Normality of the data was assessed with the Shapiro-
Wilk test. The association between TMPRSS4 expression 
and clinicopathological features of patients was analyzed 
by Pearson’s chi-square test. Relapse free survival (RFS) 
and overall survival (OS) were evaluated with Kaplan-
Meier curves and significant differences among groups 
were assessed by the logRank test. Overall survival was 
defined as the time from study enrollment to death. To 
evaluate the prognostic value of TMPRSS4, univariate and 
multivariate Cox proportional hazard analyses were used. 
To assess statistical differences between groups when 
comparing TMPRSS4 promoter methylation status in 
tumor versus non-malignant samples, the Mann-Whitney 
U test was used. Comparison of H-score for TMPRSS4 
expression between non-malignant and malignant samples 
was assessed with T-test.
To classify patients with respect to their methylation 
levels in specific CpGs, we set a threshold β-value of 0.5 
to define non-methylation (β<0.5) vs. methylation based 
on averaged 95th percentile for control samples. Data 
was analyzed with the SPSS statistical software (version 
17.0 for Windows SPSS) and GraphPad Prism 5 software 
(GraphPad). Statistical significance was defined as p<0.05 
(*), p<0.01 (**), and p<0.001 (***).
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